<DOC>
	<DOC>NCT00444860</DOC>
	<brief_summary>The purpose of this study is to obtain safety and immunogenicity data for the refrigerator-stable formulation of ZOSTAVAX(R) in taiwanese adults.</brief_summary>
	<brief_title>ZOSTAVAX(R) Local Registration Trial (V211-019)</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<criteria>Subject Is Older Than 50 Years Of Age On Day Of Signing Informed Consent All Females Must Be Postmenopausal Or Have A Negative Serum Or Urine Pregnancy Test Postmenopausal Is Defined As 6 Months Of Spontaneous Amenorrhea With Serum Follicle Stimulating Hormone (Fsh) Levels In The Postmenopausal Range As Determined By The Laboratory, Or 12 Months Of Spontaneous Amenorrhea A Subject Who Is Of Reproductive Potential Must Agree To Remain Abstinent Or Use (Or Have Her Partner Use) 2 Acceptable Methods Of Birth Control For Three Months After Vaccination Acceptable Methods Of Birth Control Are: Intrauterine Device, Diaphragm With Spermicide, Contraceptive Sponge, Oral Contraceptive Pills, Condom, Tubal Ligation, And Vasectomy Subject Must Sign Informed Consent Prior To Any Study Procedure Subject Must Be afebrile (&lt;38.3 Â°C Oral) On Day Of Vaccination Any Underlying Chronic Illness Must Be In Stable Condition</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>